Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>UBS: GALAXY ENT (00027.HK) 4Q25 Adj. EBITDA in Line; Rating Buy
Recommend 1 Positive 4 Negative 2 |
||||
|
||||
|
GALAXY ENT (00027.HK)'s 4Q25 adjusted EBITDA was approx. $4.3 billion, up about 33% YoY and about 29% QoQ, according to UBS' research report. Adjusted for VIP hold, the EBITDA would be approx. $3.6 billion, up 9% YoY and 7% QoQ, in line with estimation. Furthermore, GALAXY ENT announced a final DPS of $0.8, higher than the market consensus of $0.65, bringing the full-year DPS to $1.5, equivalent to a dividend payout ratio of about 61%, compared to 50% in 2024. Therefore, the broker rated GALAXY ENT at Buy, with a target price of $46.9. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
